ZIOPHARM Oncology Inc (ZIOP) : 1 brokerage houses believe that ZIOPHARM Oncology Inc (ZIOP) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on ZIOPHARM Oncology Inc (ZIOP). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 5 Wall Street Analysts endorse the stock as a Hold with a rating of 3.
ZIOPHARM Oncology Inc (ZIOP) : The highest short term price target forecast on ZIOPHARM Oncology Inc (ZIOP) is $21 and the lowest target price is $7. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $14 with a standard deviation of $9.9.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.80 and $5.74 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.05. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.97, notching a gain of 2.75% for the day. The total traded volume was 1,963,548 . The stock had closed at $5.81 on the previous day.
Also, Raymond James initiates coverage on ZIOPHARM Oncology Inc (NASDAQ:ZIOP). Raymond James has a Market Perform rating on the shares. The rating by the firm was issued on June 2, 2016. The company shares have dropped -45.45% from its 1 Year high price. On Nov 10, 2015, the shares registered one year high at $14.93 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $6.55 and the 200 Day Moving Average price is recorded at $7.10.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).